Publication: Aspirin: 120 years of innovation. A report from the 2017 Scientific Conference of the International Aspirin Foundation, 14 September 2017, Charité, Berlin
Open/View Files
Date
2018
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Cancer Intelligence
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Walker, J., P. Hutchison, J. Ge, D. Zhao, Y. Wang, P. M. Rothwell, J. M. Gaziano, et al. 2018. “Aspirin: 120 years of innovation. A report from the 2017 Scientific Conference of the International Aspirin Foundation, 14 September 2017, Charité, Berlin.” ecancermedicalscience 12 (1): 813. doi:10.3332/ecancer.2018.813. http://dx.doi.org/10.3332/ecancer.2018.813.
Research Data
Abstract
Acetylsalicylic acid was first synthesised by Dr FeIix Hoffman on 10th August 1897 and Aspirin was born. It quickly became the best-known pain killer in the world and in the 120 years since this event, aspirin has continued to attract interest, innovation and excitement. Set within the walls of the preserved ruins of Rudolf Virchow’s lecture hall at Charité, within Berlin’s Museum of Medical History, the International Aspirin Foundation’s 28th Scientific Conference served to facilitate international, multi-disease, multidisciplinary discussion about the current understanding of aspirin’s mechanisms of action and its utility in modern medicine as well as ideas for future research into its multifaceted applications to enhance global health. In addition to the delegates in Berlin, 300 medical doctors at the 19th Annual Scientific Congress of the Chinese Society of Cardiology were able to join the cardiology sessions from Taiyuan, Shangxi province via a live streaming link to and from China. This led to useful discussion and allowed a truly international perspective to the meeting.
Description
Other Available Sources
Keywords
aspirin, inflammation, primary prevention, secondary prevention, tertiary prevention, colorectal cancer (CRC), cardiovascular disease (CVD), stroke, bleeding, risk, benefit, Lynch syndrome, precision medicine, individualised choice, personalised medicine
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service